Thinking slows down. Words that used to come easily get stuck. Familiar places start to feel unfamiliar. It's not aging — it's your brain losing the energy it needs to function.
Dementia treatment depends on the type — vascular, Lewy body, frontotemporal — but the playbook is similar across all of them. Cholinesterase inhibitors and memantine provide modest symptomatic relief. Behavioral symptoms get managed with antipsychotics and antidepressants, both carrying risk in elderly patients. Cognitive stimulation therapy and occupational therapy help maintain function. No approved treatment reverses cognitive decline or addresses the underlying cerebrovascular insufficiency and mitochondrial failure that starve brain cells of energy.
Hadanny et al. (2020) published in Aging a prospective study of elderly adults over 64 with cognitive decline who received 60 HBOT sessions. Participants showed significant improvements in attention, information processing speed, and executive function. MRI perfusion imaging revealed a 16.5% average increase in cerebral blood flow, with the greatest gains in regions most affected by age-related hypoperfusion.1
Efrati et al. (2013) demonstrated in PLOS ONE that HBOT can neuroplastically reactivate damaged brain tissue even years after the original injury. While this study focused on post-stroke patients, the mechanism — restoring metabolic function in hypoxic-but-viable neurons — applies directly to the hypoperfused brain tissue seen in vascular and mixed dementia.2
Chen et al. (2017) published in Neural Regeneration Research that HBOT reduced oxidative stress markers and improved mitochondrial membrane potential in brain tissue, while promoting neurogenesis and synaptogenesis. Treated subjects showed improved spatial learning and memory retention compared to controls.3
Saltmarche et al. (2017) reported in Photomedicine and Laser Surgery that transcranial PBM at 810nm produced significant cognitive improvement in five patients with dementia over 12 weeks. Caregivers noted better conversation, less anxiety, improved sleep, and fewer episodes of wandering. MMSE scores improved meaningfully in all participants.4
Chao (2019) conducted a randomized controlled pilot study published in Photobiomodulation, Photomedicine, and Laser Surgery using transcranial near-infrared LED therapy in patients with dementia. The treatment group showed improved executive function, clock drawing, and verbal fluency compared to placebo, with sustained benefits through follow-up.5
Cassano et al. (2019) reviewed in Neurophotonics the evidence for transcranial PBM in neurodegenerative conditions, documenting that 810nm near-infrared light penetrates the skull sufficiently to modulate cortical cytochrome c oxidase activity, improve mitochondrial respiration, reduce neuroinflammation, and enhance cerebral oxygenation — mechanisms directly relevant to all forms of dementia.6